Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12520MR)

This product GTTS-WQ12520MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12520MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ233MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ9487MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ9835MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ8052MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ15202MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ14393MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ10265MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ15027MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW